{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:47:11Z","timestamp":1791985631191,"version":"4.4.0"},"reference-count":57,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000997","name":"Arnold and Mabel Beckman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000997","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Center for Washington Entrepreneurial Research Evaluation and Commercialization Hub"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 AI07140"],"award-info":[{"award-number":["T32 AI07140"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2026,10,14]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The World Health Organization (WHO) recommends human immunodeficiency virus (HIV) drug resistance testing (DRT), but current tests are too complex and expensive for routine use. Genotypic DRT is challenging to interpret because of the growing list of mutations responsible for HIV drug resistance. Although phenotypic DRT is simpler to interpret, it requires slow and labor-intensive viral culture. Phenotypic tests that measure the activity of isolated HIV enzymes are faster and less labor-intensive, but none have yet met the 2023 WHO Target Product Profile (TPP) for HIV DRT. Here, we present an optimized product-enhanced reverse transcriptase (PERT) assay for sensitive and quantitative detection of HIV viral load and drug resistance. PERT combines complementary DNA (cDNA) synthesis by HIV-reverse transcriptase (HIV-RT) with cDNA amplification and detection by quantitative PCR (qPCR). We established sensitive detection down to 10 HIV-RT molecules in a 25 \u00b5L sample corresponding to a viral load of ~10 HIV RNA copies\/mL. We demonstrated the assay\u2019s feasibility for phenotypic DRT using lamivudine-5\u2032-triphosphate (3TC-TP)\u2014to which the M184V mutation confers high-level resistance\u2014and quantified 3TC-TP inhibition using the difference in cDNA produced between drug and no-drug conditions. We surpassed WHO minimal analytical sensitivity requirements (20% low-abundance variant detection) by differentiating 10% M184V HIV-RT fractions in heterogeneous mixtures (1,000 total HIV-RT, viral load ~2,500 copies RNA\/mL). Finally, we showed that PERT could detect resistance to existing and emerging RT inhibitors, including tenofovir-diphosphate (TFV-DP), doravirine (DOR), and islatravir (ISL)-TP.<\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>Although antiretroviral therapy can effectively treat and prevent HIV infection, treatment efficacy and global control of the HIV epidemic are threatened by rising rates of HIV drug resistance. Inexpensive and decentralized HIV drug resistance testing (DRT) could facilitate surveillance efforts to understand the prevalence of HIV drug resistance in local and global contexts. This need is especially timely and pressing considering anticipated increased rates of HIV acquisition and drug resistance due to the reductions in global HIV services driven by recent funding cuts. Our optimized product-enhanced reverse transcriptase (PERT) assay for simultaneous viral load and phenotypic drug resistance quantification is fast (~2 h), sensitive, and accurate. We can also leverage existing RT-qPCR instruments used for viral load measurement to significantly improve access to HIV drug resistance monitoring and tailored regimen selection.<\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/jcm.01838-25","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:00:37Z","timestamp":1788181237000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["An optimized product-enhanced reverse transcriptase assay for sensitive and quantitative detection of HIV viral load and phenotypic drug resistance"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6834-3681","authenticated-orcid":false,"given":"Dorothy K.","family":"Mims","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00cvxb145","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Bioengineering, University of Washington","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Chang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00cvxb145","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Bioengineering, University of Washington","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4776-1774","authenticated-orcid":true,"given":"Ayokunle O.","family":"Olanrewaju","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00cvxb145","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Bioengineering, University of Washington","place":["Seattle, USA"]},{"id":[{"id":"https:\/\/ror.org\/00cvxb145","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Mechanical Engineering, University of Washington","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Global Statistics. 2025. HIV.gov. Available from: https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/global-statistics"},{"key":"e_1_3_3_3_2","unstructured":"HIV Care Continuum. 2025. HIV.gov. Available from: https:\/\/www.hiv.gov\/federal-response\/other-topics\/hiv-aids-care-continuum"},{"key":"e_1_3_3_4_2","unstructured":"World Health Organization. 2022. The role of HIV viral suppression in reducing transmission and improving individual health: policy brief. Geneva"},{"key":"e_1_3_3_5_2","unstructured":"Virologic Failure and Antiretroviral Options NIH. 2021. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/virologic-failure"},{"key":"e_1_3_3_6_2","unstructured":"Bello G. 2024. Emerging dolutegravir resistance among children being investigated for treatment failure in Malawi"},{"key":"e_1_3_3_7_2","unstructured":"World Health Organization. 2024. HIV drug resistance: brief report 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240086319."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25501"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.11.002"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2015.07.001"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2012.02.001"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-01751-9"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13061125"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11070724"},{"key":"e_1_3_3_15_2","unstructured":"PhenoSense. Monogram Biosciences. Available from: https:\/\/monogrambio.labcorp.com\/resources\/phenotyping\/phenosense"},{"key":"e_1_3_3_16_2","unstructured":"World Health Organization. 2023. Target product profile for HIV drug resistance tests in low- and middle-income countries: Africa. https:\/\/www.who.int\/publications\/i\/item\/9789240076662."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-018-9390-x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022019"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.47456-0"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2014.02.021"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","unstructured":"Wang Q Kline EC Gilligan-Steinberg SD Lai JJ Hull IT Olanrewaju AO Panpradist N Lutz BR. 2024. Sensitive pathogen detection and drug resistance characterization using pathogen-derived enzyme activity amplified by LAMP or CRISPR-Cas. HIV\/AIDS. doi:10.1101\/2024.03.29.24305085","DOI":"10.1101\/2024.03.29.24305085"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/life12081130"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-245-7:291"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3377-3383.2003"},{"key":"e_1_3_3_25_2","unstructured":"World Health Organization. 2018. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-HIV-18.51."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2009.01.002"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(92)90593-e"},{"key":"e_1_3_3_28_2","volume-title":"Retroviruses","author":"Coffin JM","year":"1997","unstructured":"Coffin JM, Hughes SH, Varmus HE. 1997. Reverse transcription of the viral genome in vivo. In Retroviruses. Cold Spring Harbor Laboratory Press."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.14.6537-6546.2001"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-0934(96)02078-2"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33804-1"},{"key":"e_1_3_3_32_2","volume-title":"Antiretroviral resistance in clinical practice","author":"Luca A","year":"2006","unstructured":"Luca A. 2006. The impact of resistance on viral fitness and its clinical implications. In Geretti AM (ed), Antiretroviral resistance in clinical practice. Mediscript, London."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308806200"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2008.10.012"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050859"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-017-8544-6"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9121047"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/515272"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00097-18"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/v16111682"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.2.264"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.10.2231"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1086\/378281"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02223-21"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","unstructured":"Cilento ME Wen X Reeve AB Ukah O Snyder A Carrillo CM Smith CP Edwards K Wahoski CC Kitzler DR Kodama EN Mitsuya H Parniak MA Tedbury PR Sarafianos SG. 2023. HIV-1 resistance to islatravir\/tenofovir combination therapy in wild-type or NRTI resistant strains of diverse HIV-1 subtypes. Microbiology. doi:10.1101\/2023.06.18.545484","DOI":"10.1101\/2023.06.18.545484"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.022525"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106157"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04201-14"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00074-09"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-01104"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00074-8"},{"key":"e_1_3_3_52_2","unstructured":"Clinton Health Access Initiative. 2023. 2023 HIV market report. https:\/\/www.clintonhealthaccess.org\/report\/2023-hiv-market-report-the-state-of-hiv-market-in-low-and-middle-income-countries\/."},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101609"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00228-X"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae185"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30036-2"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0109"},{"key":"e_1_3_3_58_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. 2025 Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01838-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.01838-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:03:48Z","timestamp":1791983028000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.01838-25"}},"subtitle":[],"editor":[{"given":"Randall","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,14]]}},"alternative-id":["10.1128\/jcm.01838-25"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01838-25","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"2025-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01838-25"}}